BRPI0716375A2 - Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito... - Google Patents

Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito...

Info

Publication number
BRPI0716375A2
BRPI0716375A2 BRPI0716375-4A2A BRPI0716375A BRPI0716375A2 BR PI0716375 A2 BRPI0716375 A2 BR PI0716375A2 BR PI0716375 A BRPI0716375 A BR PI0716375A BR PI0716375 A2 BRPI0716375 A2 BR PI0716375A2
Authority
BR
Brazil
Prior art keywords
subject
sedation
anesthesia
respiratory depression
reducing
Prior art date
Application number
BRPI0716375-4A2A
Other languages
English (en)
Inventor
John James Greer
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Publication of BRPI0716375A2 publication Critical patent/BRPI0716375A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0716375-4A2A 2006-08-31 2007-08-30 Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito... BRPI0716375A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82424506P 2006-08-31 2006-08-31
PCT/CA2007/001517 WO2008025148A1 (en) 2006-08-31 2007-08-30 Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators

Publications (1)

Publication Number Publication Date
BRPI0716375A2 true BRPI0716375A2 (pt) 2013-10-15

Family

ID=39135467

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716375-4A2A BRPI0716375A2 (pt) 2006-08-31 2007-08-30 Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito...

Country Status (13)

Country Link
US (4) US8039468B2 (pt)
EP (1) EP2061471A4 (pt)
JP (1) JP2010501597A (pt)
KR (1) KR20090047534A (pt)
CN (1) CN101600436A (pt)
AU (1) AU2007291848B2 (pt)
BR (1) BRPI0716375A2 (pt)
CA (1) CA2660431C (pt)
IL (1) IL197334A0 (pt)
MX (1) MX2009002180A (pt)
NO (1) NO20090605L (pt)
WO (1) WO2008025148A1 (pt)
ZA (1) ZA200900955B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039468B2 (en) * 2006-08-31 2011-10-18 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
KR20100045507A (ko) 2007-08-10 2010-05-03 코텍스 파마슈티칼스, 인크. 글루타메이트성 시냅스 반응을 향상시키기 위한 비시클릭 아미드
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
WO2010054336A2 (en) * 2008-11-10 2010-05-14 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US10351509B2 (en) 2015-12-22 2019-07-16 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
US20170174614A1 (en) 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
CA3032996A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156043B1 (en) 1992-07-24 2003-11-12 The Regents Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
AU4416197A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
US6943159B1 (en) * 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
SE0000601D0 (sv) * 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
US20030100552A1 (en) * 2001-05-17 2003-05-29 Boehringer Ingelheim Pharma Kg Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions
DE10123952A1 (de) * 2001-05-17 2002-11-21 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CN1390543A (zh) * 2002-07-25 2003-01-15 湖南省岳阳市制药三厂 注射用奥拉西坦药品
AU2004204814B2 (en) * 2003-01-13 2009-10-08 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
DE602006003661D1 (de) * 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
US8039468B2 (en) * 2006-08-31 2011-10-18 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators

Also Published As

Publication number Publication date
KR20090047534A (ko) 2009-05-12
US20160120873A1 (en) 2016-05-05
US20190030041A1 (en) 2019-01-31
WO2008025148A1 (en) 2008-03-06
US8039468B2 (en) 2011-10-18
ZA200900955B (en) 2011-04-28
CA2660431A1 (en) 2008-03-06
AU2007291848B2 (en) 2012-01-12
JP2010501597A (ja) 2010-01-21
US20120004219A1 (en) 2012-01-05
EP2061471A1 (en) 2009-05-27
CA2660431C (en) 2015-03-17
MX2009002180A (es) 2009-06-05
US20080261962A1 (en) 2008-10-23
EP2061471A4 (en) 2012-02-01
NO20090605L (no) 2009-03-26
IL197334A0 (en) 2009-12-24
CN101600436A (zh) 2009-12-09
AU2007291848A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
BRPI0716375A2 (pt) Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito...
IL243709A0 (en) Devices, systems and methods for drug administration
AP2258A (en) Tamper resistant dosage forms.
HK1190909A1 (zh) 用於鼻淚系統的藥物釋放方法、結構及組合物
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
NO343776B1 (no) Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
BRPI0819117A2 (pt) sistema de dispensação de composição de combustível, e, método para fornecer uma composição de combustível
BRPI0911681A2 (pt) composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula
GB0910105D0 (en) Devices, systems and methods for medicament delivery
BRPI0813201A2 (pt) "composição curável, compósito e método para formar um compósito"
ITGE20060080A1 (it) Fibbia, in particolare per maschere o simili.
BRPI0915382A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
GB2478085B (en) Devices, systems and methods for medicament delivery
SI2139457T1 (sl) Naprava za dajanje zdravila za zagotavljanje lokalne analgezije, lokalne anestezije ali živčne blokade
BRPI0905790A2 (pt) 'micropartícula, método para a fabricação de micropartícula e preparação farmacêutica
BRPI0722057A2 (pt) Composto, prodroga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono, e, uso do composto.
GB201114400D0 (en) Devices, systems and methods for medicament delivery
BRPI0807880A2 (pt) Composição anestésica em spray.
AU311136S (en) Anti-asphyxia valve clip for respiratory mask
AP2008004645A0 (en) Perfluorocarbon gas transferring emulsion for medico-biological use, the composition and the production method thereof a medicinal agent
ES1056767Y (es) Aguja perfeccionada para anestesia epidural intradural combinada.
BRPI0906045A2 (pt) "composição farmacêutica para administração nasal"
AU315291S (en) Anti-asphyxia valve clip for respiratory mask
BRPI0718633A2 (pt) Mutante de trombina, polinucleotídeo, vetor recombinante, transformante, método para produzir um mutante de trombina, e, composição farmacêutica.
ES1063301Y (es) Barandilla de seguridad mediante vallas ascendentes para andenes de tren, metro y otras aplicaciones.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.